Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a <scp>SEER</scp>‐medicare analysis
Sikander Ailawadhi(Jacksonville College), Asher Chanan‐Khan(WinnMed), Aneel Paulus(WinnMed), Zahara Meghji(Jacksonville College), Shahrukh K. Hashmi(Mayo Clinic), Mayank Sharma(Jacksonville College), Tanya Singh Kakar(All India Institute of Medical Sciences), Richa Menghani(Jacksonville College), Gerardo Colón‐Otero(Jacksonville College), Nandita Khera(Mayo Clinic in Florida), Shumail M. Paulus(Jacksonville College), M’hamed Temkit(Phoenix Children's Hospital), Dorin Colibaseanu(Mayo Clinic in Florida), David O. Hodge(WinnMed), Vivek Roy(Jacksonville College), Abhisek Swaika(Jacksonville College), Ryan D. Frank(Mayo Clinic), Michael Vizzini(Jacksonville College), Pooja Advani(Jacksonville College)
Cited by 88
Related Papers
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
|New England Journal of Medicine|2021|553
Ten-year postoperative results of penetrating keratoplasty
|Ophthalmology|1998|506
Early safety indicators of COVID-19 convalescent plasma in 5000 patients
|Journal of Clinical Investigation|2020|485